Related Experiment Videos
Prostanoids in paediatric kidney diseases
H W Seyberth1, A Leonhardt, B Tönshoff
1Department of Paediatrics, University of Marburg, Federal Republic of Germany.
Insights
Prostanoids, derived from arachidonic acid, significantly impact kidney function and disease. Understanding their roles in vasoconstriction and electrolyte balance is crucial for treating kidney disorders.
Area of Science:
- Nephrology
- Renal Physiology
- Eicosanoid Biology
Background:
- Prostanoids are eicosanoids derived from arachidonic acid, playing key roles in renal physiology and pathology.
- Specific prostanoids like thromboxane A2 (TXA2) and prostaglandin E2 (PGE2) are implicated in various kidney diseases.
Purpose of the Study:
- To explore the multifaceted roles of prostanoids in kidney function and disease.
- To review the involvement of TXA2 and PGE2 in glomerular diseases, tubular handling, and obstructive uropathies.
- To examine the protective roles of vasodilator prostanoids (PGI2, PGE2) and their involvement in drug actions.
Main Methods:
- Literature review and synthesis of existing research on prostanoids in renal pathophysiology.
- Analysis of clinical data and pharmacological studies related to prostanoid involvement.
Main Results:
- TXA2 contributes to glomerular diseases (e.g., hemolytic-uremic syndrome).
- PGE2 affects tubular electrolyte/water handling and is linked to Bartter's syndrome and other conditions.
- Prostanoids mediate effects of drugs like NSAIDs, frusemide, and ACE inhibitors.
- The role of renal prostanoids in cyclosporine toxicity remains unclear.
Conclusions:
- Prostanoids are critical mediators in renal pathophysiology, influencing diverse kidney functions and diseases.
- Future research must consider the complex interactions between prostanoids, hormones, and cytokines in the kidney.
Abstract:
Prostanoids belong to the growing family of eicosanoids, which are all derived from arachidonic acid. Prostanoids act as modulators and mediators in a large spectrum of physiological and pathophysiological processes within the kidney. On the one hand, the potent vasoconstrictor and platelet-aggregating thromboxane (TX) A2 is involved in the pathophysiology of a variety of glomerular diseases, such as haemolytic-uraemic syndrome and immune-mediated glomerulopathies. Prostaglandin (PG) E2, on the other hand, interferes with tubular electrolyte and water handling. Clinical data support the hypothesis that this member of the prostanoid family contributes to the pathophysiology of Bartter's syndrome, hyperprostaglandin E syndrome, idiopathic hypercalciuria and renal diabetes insipidus. Both prostanoids, TXA2 and PGE2, are involved in the pathophysiology of obstructive uropathies. The physiological and protective role of renal vasodilator prostanoids (PGI2 and PGE2) has been studied during treatment with non-steroidal anti-inflammatory drugs. Part of the pharmacological effects of frusemide and converting enzyme inhibitors is mediated by PGI2 and PGE2. The role of renal prostanoids in cyclosporine toxicity is still equivocal. Future investigations on the physiological and pathophysiological role of renal prostanoids will have to consider the multiple interactions between prostanoids on the one hand, and classical hormones and other mediators (e.g. cytokines) on the other hand.